Hereditary neurological disease
MONDO:0100545A heterogeneous group of genetic conditions with Mendelian (autosomal dominant, recessive, or X-linked) or chromosomal etiology characterized by abnormalities in the brain, spinal cord, nerves, or muscles.
Also known as: neurogenetic disease
5681 clinical trials for this condition and its sub-types.
Follow this condition to get notified about new trialsSub-types
Broader categories
-
Seizure drug safety trial halted early for dravet and LGS patients
Disease control Stopped earlyThis study looked at the long-term safety of soticlestat when added to standard seizure medicines for people with Dravet syndrome or Lennox-Gastaut syndrome. It included 352 children and adults who had already been in earlier studies. The trial was terminated early, so results ar…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug tame seizures in two severe epilepsy syndromes?
Disease control Stopped earlyThis phase 3 trial tests whether soticlestat can reduce seizures in people with Dravet syndrome or Lennox-Gastaut syndrome who have already used fenfluramine. Participants take soticlestat as tablets or mini-tablets, and researchers measure changes in seizure frequency over the f…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug shows promise for Tough-to-Treat seizures in kids
Disease control Stopped earlyThis study looked at the long-term safety of soticlestat, an experimental drug, in children and adults with severe forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome. Participants took soticlestat twice a day along with their usual seizure medicines. The study was…
Phase 2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Promising combo therapy for incurable liver cancer shows potential in phase 3 trial
Disease control Stopped earlyThis study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an antiviral drug protect hearing in infants with congenital CMV?
Disease control Stopped earlyThis trial tests whether the antiviral drug valganciclovir can improve hearing and language outcomes in infants who have hearing loss due to congenital cytomegalovirus (CMV) infection. Infants aged 1 to 12 months with confirmed sensorineural hearing loss will receive either valga…
Phase 2 • Sponsor: Albert Park • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Halted gene therapy study raises questions for AMN patients
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SBT101 for adrenomyeloneuropathy (AMN), a rare nerve disease that causes walking difficulties. Eight adults received either the therapy or a sham procedure. The study was terminated early, so we have limited data on safety and e…
Phase 1/2 • Sponsor: SwanBio Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Immune cells take on nerve tumors: new trial launches
Disease control Stopped earlyThis early-stage trial is testing whether specially engineered immune cells (called CAR-T and CTL cells) and a dendritic cell vaccine can safely treat people with neurofibromatosis or schwannomatosis, conditions that cause nerve tumors. The study will enroll 100 participants aged…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug cocktail aims to extend life in advanced esophageal cancer
Disease control Stopped earlyThis study tests whether adding lenvatinib to pembrolizumab and chemotherapy helps people with metastatic esophageal cancer live longer. About 864 participants receive either the new three-drug combo or standard care. The goal is to improve overall survival, but this is not a cur…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New hope for High-Risk melanoma: combo therapy aims to prevent recurrence
Disease control Stopped earlyThis study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Experimental drug REC-2282 targets NF2 brain tumors in early trial
Disease control Stopped earlyThis study tested a drug called REC-2282 in people aged 12 and older with progressive meningiomas (brain tumors) linked to NF2 gene mutations. Participants took the drug or a placebo three times a week in cycles. The goal was to see if the drug could slow tumor growth. The trial …
Phase 2/3 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control Stopped earlyThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a previous study will receive the spray three times daily. The goal is to see …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New eye injection targets Blindness-Causing lesions
Disease control Stopped earlyThis early-stage study tests the safety of an experimental drug called RO7669330, given as an injection into the eye, for people with geographic atrophy (GA) due to age-related macular degeneration (AMD). The study involves 27 participants and will monitor side effects and eye he…
Phase 1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Virtual cues on a treadmill: a new hope for Parkinson's falls?
Disease control Stopped earlyThis trial tests whether adding augmented reality (AR) to treadmill training can help people with Parkinson's disease who have trouble walking and are at risk of falling. Participants will be randomly assigned to one of three groups: treadmill training with AR, treadmill training…
Sponsor: Klinik Valens • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat lymphomas
Disease control Stopped earlyThis study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Could a gel cut down on skin cancer surgeries? new trial investigates
Disease control Stopped earlyThis trial tests a gel called patidegib applied to the face twice daily for 9 months in people who develop many basal cell carcinomas (a common skin cancer) but do not have Gorlin syndrome. The goal is to see if the gel reduces the number of new skin cancers that would normally r…
Phase 2 • Sponsor: Sol-Gel Technologies, Ltd. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Light-Activated cream could slow growth of NF1 skin tumors
Disease control Stopped earlyThis trial tests whether a light-activated cream (Levulan Kerastick) followed by red light therapy can slow the growth of benign skin tumors called neurofibromas in people with neurofibromatosis type 1 (NF1). About 30 participants aged 14 and older with superficial tumors on the …
Phase 2 • Sponsor: Donald Basel • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Genetic clues could personalize breast cancer treatment
Disease control Stopped earlyThis study looks at genetic changes in postmenopausal women with a common type of advanced breast cancer (HR+ HER2-). Participants first receive ribociclib plus letrozole; those with a specific mutation (PIK3CA) may later switch to alpelisib plus fulvestrant. The goal is to track…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Experimental Friedreich's ataxia drug tested in kids – but trial halted early
Disease control Stopped earlyThis early-stage trial tested a drug called nomlabofusp (CTI-1601) in 18 adolescents and children with Friedreich's ataxia, a rare genetic disease that affects movement and coordination. The goal was to check safety and how the body processes the drug. However, the study was term…
Phase 1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Real-World study tracks Selumetinib's impact on NF1 tumors in children
Disease control Stopped earlyThis study observes children aged 3 to 18 with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas and are starting treatment with selumetinib. Researchers will track how well the drug shrinks or stabilizes tumors, how long patients stay on tre…
Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control Stopped earlyThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a common blood pressure drug shrink kidney tumors?
Disease control Stopped earlyThis pilot study tested whether propranolol, a beta-blocker, could shrink or stabilize kidney angiomyolipomas in people with tuberous sclerosis. Only 2 participants were enrolled before the trial was terminated, so the results are very limited. The goal was to find a less invasiv…
Phase 2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Tiny doses of avastin tested against laser for preemie eye disease
Disease control Stopped earlyThis study tested a low dose of the drug bevacizumab (Avastin) against standard laser treatment for retinopathy of prematurity, an eye disease that can blind premature infants. Sixteen babies with severe disease were enrolled. The goal was to see if the drug could control the dis…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Gene therapy trial for rare childhood epilepsy halted after just one patient
Disease control Stopped earlyThis trial tested a single dose of CAP-002 gene therapy in children aged 18 months to 8 years with STXBP1 encephalopathy, a rare genetic brain disorder causing seizures and developmental delays. The study aimed to check safety and whether it could reduce seizures and improve skil…
Phase 1/2 • Sponsor: Capsida Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental cancer drug trial halted early
Disease control Stopped earlyThis early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental cancer drug study halted early
Disease control Stopped earlyThis early-stage study tested a new drug called PF-07284892, alone or with other medicines, in people with advanced solid tumors that had specific genetic changes. The goal was to find the safest dose and check for side effects. The study was stopped early, so results are limited…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill for rheumatoid arthritis shows promise in early trial
Disease control Stopped earlyThis phase 2 study tested an experimental oral drug called BGB-45035 in 49 adults with moderate to severe rheumatoid arthritis who had not responded well to standard treatments. Participants received either the drug or a placebo to see if it could reduce joint pain and swelling. …
Phase 2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Promising seizure drug study halted early
Disease control Stopped earlyThis study looked at the long-term safety of the drug NBI-921352 for people with a rare genetic seizure disorder called SCN8A-DEE. It was an extension of an earlier study, and participants took the drug alongside their usual seizure medications. The study was stopped early and on…
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Can a daily injection reshape bodies of HIV patients?
Disease control Stopped earlyThis study looked at whether tesamorelin (Egrifta), a daily injection that boosts growth hormone, can improve body composition in people with HIV who have excess belly fat (lipodystrophy). Six participants received the drug for up to 12 months, with researchers measuring liver fa…
Phase 4 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Anti-Inflammatory drug studied for PANDAS-Related OCD in kids
Disease control Stopped earlyThis study tested the anti-inflammatory drug naproxen sodium for treating obsessive-compulsive symptoms in children aged 6-15 with PANDAS, a condition linked to strep infections. The trial was double-blind and placebo-controlled, but it was terminated early after enrolling only 2…
Phase 4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Warming blankets and fluids tested to prevent hypothermia in C-Section births
Disease control Stopped earlyThis study tested different warming methods—like forced air blankets and warmed IV fluids—to prevent hypothermia in women having planned C-sections. Only 16 women participated before the trial was stopped early. The goal was to see which method best keeps mother and baby warm and…
Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New cocktail of cancer drugs tested in desperate cases
Disease control Stopped earlyThis early-phase trial tested combinations of the drugs bevacizumab and temsirolimus, sometimes with valproic acid or cetuximab, in 154 people with advanced cancers or certain non-cancerous but progressive diseases. The main goal was to find safe doses and look for any signs that…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New prostate cancer combo trial ends early
Disease control Stopped earlyThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…
Phase 1/2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Continued EryDex treatment studied in rare neurological disorder
Disease control Stopped earlyThis study offered continued treatment with EryDex to 101 people with ataxia telangiectasia (A-T) who had finished a previous trial. The main goal was to monitor safety, including side effects and serious events. The study was terminated early, and it did not aim to cure the dise…
Phase 3 • Sponsor: Quince Therapeutics S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a repurposed drug tame seizures in adult dravet patients?
Disease control Stopped earlyThis study tested the drug fenfluramine (FINTEPLA) in adults with Dravet syndrome whose seizures were not controlled by other medications. The trial was open-label and added fenfluramine to existing treatments. It aimed to see if the drug could reduce monthly seizures by at least…
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental Parkinson's drug talineuren put to early safety test
Disease control Stopped earlyThis early-stage trial tested the safety of an intravenous drug called talineuren (liposomal GM1) in 22 people with Parkinson's disease. The study was open-label and designed to find a safe dose, but it was terminated before completion. No conclusions about effectiveness can be d…
Phase 1 • Sponsor: InnoMedica Schweiz AG • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope dashed: drug trial for Post-COVID racing heart stopped early
Disease control Stopped earlyThis study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug TPN-101 tested in rare childhood brain disease
Disease control Stopped earlyThis study tested a drug called TPN-101 (censavudine) in people with Aicardi-Goutières syndrome, a rare genetic disorder that causes severe brain inflammation. The trial enrolled only 4 participants and aimed to see if the drug could reduce immune system overactivity and check fo…
Phase 2 • Sponsor: Transposon Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Parkinson's drug trial halted: what we learned from UCB0599
Disease control Stopped earlyThis study looked at whether taking UCB0599 early or later could slow brain changes in people with Parkinson's disease. It involved 428 adults who had already completed an earlier study. The trial was stopped early, but researchers measured brain scans and medication use over 18 …
Phase 2 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
DMD drug tested in wheelchair users – but trial stops early
Disease control Stopped earlyThis study tested the safety of golodirsen (Vyondys 53) in boys and men with Duchenne muscular dystrophy who can no longer walk. Only 2 people took part before the trial was stopped early. Participants received weekly IV infusions for up to 96 weeks, with extra follow-up. The goa…
Phase 4 • Sponsor: Rare Disease Research, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control Stopped earlyThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Epilepsy drug study halted early: BHV-7000 shows limited promise
Disease control Stopped earlyThis study tested whether BHV-7000, taken alongside other medications, could reduce generalized tonic-clonic seizures in people with idiopathic generalized epilepsy. The trial was terminated early and enrolled only 27 adults aged 18-75. The main goal was to see how long it took f…
Phase 2/3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental drug shows promise for rare genetic disorder
Disease control Stopped earlyThis Phase II trial tested a drug called N-Acetyl-L-Leucine (IB1001) in 17 people with Ataxia-Telangiectasia, a rare genetic disease that affects movement and immunity. The study aimed to see if the drug could improve symptoms and slow the disease over time. The trial was termina…
Phase 2 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental kidney cancer drug trial halted early
Disease control Stopped earlyThis early-stage trial tested a new drug called DFF332, which targets a protein (HIF2α) that helps some cancers grow. The study included 40 adults with advanced clear cell renal cell carcinoma or other cancers with specific gene changes. DFF332 was tested alone and in combination…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
OCD drug trial halted early: what happened with troriluzole?
Disease control Stopped earlyThis study looked at the long-term safety of a drug called troriluzole for people with obsessive-compulsive disorder (OCD) who hadn't improved enough with standard treatments. The trial planned to enroll 772 participants but was terminated early. The main goal was to check for si…
Phase 3 • Sponsor: Biohaven Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Experimental cancer drug tested in rare tumors, but trial stopped early
Disease control Stopped earlyThis phase 2 trial tested the drug guadecitabine (SGI-110) in people aged 12 and older with rare cancers like wild-type GIST, pheochromocytoma, paraganglioma, and HLRCC-related kidney cancer that had not responded to other treatments. Participants received daily injections for 5 …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Virus therapy fails to advance in colorectal cancer trial
Disease control Stopped earlyThis study tested a new approach using a virus that attacks cancer cells (oncolytic immunotherapy) along with two standard drugs (atezolizumab and bevacizumab) in people with advanced colorectal cancer that had stopped responding to other treatments. The trial was stopped early a…
Phase 2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
Disease control Stopped earlyThis early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or…
Phase 1/2 • Sponsor: Enterome • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control Stopped earlyThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Hope fades: trial of Tay-Sachs drug venglustat terminated early
Disease control Stopped earlyThis Phase 3 trial tested an oral drug called venglustat in 75 adults and children with late-onset Tay-Sachs or Sandhoff disease, rare genetic disorders that cause progressive nerve damage. The drug aimed to lower toxic fat buildup in the brain and slow disease worsening. However…
Phase 3 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy shot for dry AMD shows promise but trial halted early
Disease control Stopped earlyThis study tested a single injection of GT005, a gene therapy, in 255 people with geographic atrophy from dry age-related macular degeneration. The goal was to see if it could slow the growth of blind spots in the eye. The trial was terminated early, so we have less data than hop…
Phase 2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Experimental gene injection targets dry AMD
Disease control Stopped earlyThis early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but w…
Phase 1/2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Gene therapy zolgensma tested in kids with SMA who can sit but not stand
Disease control Stopped earlyThis phase 1 trial tested a gene therapy called AVXS-101 (Zolgensma) in 32 children with spinal muscular atrophy (SMA) who could sit but not stand or walk. The therapy delivers a working SMN gene via a spinal injection to help improve muscle function. The study focused on safety …
Phase 1 • Sponsor: Novartis Gene Therapies • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Neurodegenerative drug study ends early after only 17 participants
Disease control Stopped earlyThis study was designed to let people who had already taken latozinemab in an earlier study continue receiving the drug. Only 17 people took part, and the study was stopped early. The goal was to track safety and how long people stayed on treatment, not to test if the drug could …
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Hope for genetic dementia: AL001 trial ends early
Disease control Stopped earlyThis phase 3 study tested a drug called AL001 in 119 people who carry a mutation in the progranulin gene, putting them at high risk for or already diagnosed with frontotemporal dementia. The goal was to see if AL001 could slow the worsening of memory, behavior, and language probl…
Phase 3 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy for rare muscle disease shows early promise but study halted
Disease control Stopped earlyThis study tested a gene therapy called SRP-9003 for people with limb-girdle muscular dystrophy type 2E (LGMD2E), a rare genetic disease that causes muscle weakness. The treatment aimed to deliver a working gene to muscle cells to help them produce a missing protein. Only 6 peopl…
Phase 1/2 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental gene therapy aims to halt vision loss in rare blindness
Disease control Stopped earlyThis study tested a gene therapy for retinitis pigmentosa, an inherited eye disease that causes gradual vision loss. The treatment involved injecting a corrected gene under the retina in one eye. The trial included 19 people aged 13 and older with a specific genetic defect. The m…
Phase 1/2 • Sponsor: eyeDNA Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Huntington's drug safety study halted early
Disease control Stopped earlyThis study aimed to see if the drug SAGE-718 is safe for people with Huntington's disease when taken over a long period. It was an open-label study, meaning everyone knew they were getting the drug. The study was terminated early, so results are limited.
Phase 3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
ALS drug trial halted: safety data sought from 54 patients
Disease control Stopped earlyThis study tested a new drug called VRG50635 in 54 people with ALS (Lou Gehrig's disease). The main goal was to check if the drug is safe and how the body processes it. The trial was stopped early, but researchers were looking for side effects and changes in disease progression.
Phase 1 • Sponsor: Verge Genomics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Eye injections tested to save sight in rare coats disease
Disease control Stopped earlyThis study tested whether anti-VEGF injections into the eye could help treat Coats disease, a rare condition that causes abnormal blood vessels and fluid buildup in the retina, potentially leading to blindness. The trial included 18 people with early-stage Coats disease who had n…
Phase 3 • Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy plus radiation for early lung cancer: trial halted early
Disease control Stopped earlyThis phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Experimental drug AR-42 tested on brain tumors – early results uncertain
Disease control Stopped earlyThis early-phase trial tested the drug AR-42 in 7 adults with vestibular schwannoma or meningioma brain tumors who were already scheduled for surgery. Participants took AR-42 pills for about 3 weeks before their operation. The main goal was to see if the drug could lower a protei…
Early phase 1 • Sponsor: Massachusetts Eye and Ear Infirmary • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Experimental drug losmapimod tested in rare muscle disease – early hopes, but trial cut short
Disease control Stopped earlyThis study tested an experimental drug called losmapimod in 14 adults with FSHD1, a rare genetic condition that causes progressive muscle weakness. The main goal was to check safety and tolerability, and to see if the drug affects certain biological markers. The trial was termina…
Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug trial for duchenne MD halted early – what we know
Disease control Stopped earlyThis phase 2 study tested a drug called PGN-EDO51 in 7 people with Duchenne muscular dystrophy whose genetic mutation can be corrected by skipping exon 51. The drug was given by IV infusion to see if it is safe and tolerable. The trial was terminated, so results are limited.
Phase 2 • Sponsor: PepGen Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Promising cream for rare skin condition falls short in early trial
Disease control Stopped earlyThis study tested a sirolimus cream (0.2% and 0.4%) applied daily for 12 weeks to treat facial angiofibromas in children aged 2-21 with tuberous sclerosis complex. The goal was to see if the cream could safely reduce the size and redness of these skin growths. The trial was termi…
Phase 2 • Sponsor: Aucta Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental gene therapy for DMD hits antibody barrier – study halted
Disease control Stopped earlyThis study tested a gene therapy (delandistrogene moxeparvovec) combined with a drug called imlifidase to see if it could safely deliver the therapy to boys with Duchenne muscular dystrophy who had antibodies that might block the treatment. Only 5 participants were planned, but t…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New surgical trick may fix stubborn eye holes
Disease control Stopped earlyThis study tested a new surgical technique for macular holes that remained open after standard treatment. The procedure involves moving a thin membrane from the eye to cover the hole. Only 16 people were enrolled, and the study was stopped early, so we don't yet know if this appr…
Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
FSHD drug trial halted midway: what happened?
Disease control Stopped earlyThis study tested a drug called losmapimod for people with a rare muscle-weakening disease called FSHD. The goal was to see if the drug could slow muscle loss and improve arm function over 48 weeks. About 260 adults with FSHD were randomly assigned to receive either losmapimod or…
Phase 3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Experimental cell therapy targets deadly childhood brain cancer
Disease control Stopped earlyThis early-phase trial tested a new immunotherapy approach for children with DIPG, a rare and aggressive brain stem tumor. After standard radiation and chemotherapy, patients received special vaccines and immune cells designed to attack the tumor. The study was small (11 particip…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Parkinson's drug trial halted early: what happened?
Disease control Stopped earlyThis study tested an experimental drug called VENT-02 in 29 people with mild to moderate Parkinson's disease. The drug aims to reduce brain inflammation by blocking a protein called NLRP3. The trial was terminated early, so we don't have clear results on whether it helps symptoms…
Phase 1/2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug for Post-COVID POTS study halted early
Disease control Stopped earlyThis study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study.…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental gene therapy targets duchenne MD in young boys
Disease control Stopped earlyThis Phase 2 trial tested a single dose of gene therapy (fordadistrogene movaparvovec) in 10 boys with early-stage Duchenne muscular dystrophy. The goal was to check safety and whether the therapy could help muscles produce a mini-dystrophin protein. The study was terminated earl…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Gene therapy for duchenne muscular dystrophy under Long-Term watch
Disease control Stopped earlyThis study follows 7 people with Duchenne muscular dystrophy who previously received an experimental gene therapy called fordadistrogene movaparvovec. Researchers will monitor them for 10 years to check for side effects and see if the treatment continues to help with movement. Th…
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Promising epilepsy drug trial halted early – what we know
Disease control Stopped earlyThis study tested an experimental drug called NBI-921352 in people aged 2 to 21 with a rare, severe form of epilepsy caused by a change in the SCN8A gene. The goal was to see if adding this drug to their current seizure medicines could reduce how often they had seizures. The tria…
Phase 2 • Sponsor: Neurocrine Biosciences • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Dravet syndrome drug trial halted early: did lorcaserin help?
Disease control Stopped earlyThis study tested whether lorcaserin, when added to current medications, could reduce convulsive seizures in people with Dravet syndrome, a severe form of epilepsy. The trial planned to enroll about 22 participants aged 2 and older, but it was terminated early. The main goal was …
Phase 3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental cancer cocktails show promise, but study halted early
Disease control Stopped earlyThis early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental drug losmapimod tested for rare muscle disease
Disease control Stopped earlyThis phase 2 trial tested the drug losmapimod in 76 adults with FSHD, a genetic condition that causes progressive muscle weakness. Participants took either losmapimod or a placebo for 48 weeks to see if the drug was safe and could help control the disease. The study was terminate…
Phase 2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental seizure drug tested in rare genetic disorder
Disease control Stopped earlyThis phase 3 study tested the drug ganaxolone as an add-on treatment for seizures in children and adults with tuberous sclerosis complex (TSC). The trial was open-label, meaning everyone received the drug, and it included 117 people who had previously been in related studies. The…
Phase 3 • Sponsor: Marinus Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Experimental drug zavesca tested for rare fatal brain diseases in infants
Disease control Stopped earlyThis phase 3 trial tested the drug miglustat (Zavesca) in 30 infants with Sandhoff or Tay-Sachs diseases, rare genetic disorders that destroy nerve cells. The goal was to see if the drug could reduce hospitalizations, seizures, and feeding problems while improving motor function.…
Phase 3 • Sponsor: Tehran University of Medical Sciences • Aim: Disease control
Last updated Jun 26, 2026 17:51 UTC
-
Gene therapy trial for duchenne MD halted early – what we know
Disease control Stopped earlyThis early-stage trial tested a single infusion of gene therapy (PF-06939926) in 23 people with Duchenne muscular dystrophy, both those who could still walk and those who could not. The main goal was to check safety and tolerability, while also measuring dystrophin protein levels…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 26, 2026 17:12 UTC
-
Eye drug trial halted: could danicopan still slow blind spots?
Disease control Stopped earlyThis Phase 2 study tested an oral drug called danicopan in 365 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. Participants took different doses of danicopan or a placebo for up to 104 weeks to see if it could slow…
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:21 UTC
-
Can plasma exchange clear the way for gene therapy in duchenne?
Disease control Stopped earlyThis early study tested whether a blood-cleaning procedure called plasmapheresis could allow boys with Duchenne muscular dystrophy who have antibodies against the gene therapy carrier to still receive the treatment. Only 3 boys were enrolled before the study was stopped early. Th…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy for rare muscle disease tested in just 2 people
Disease control Stopped earlyThis was a very early (Phase 1) study testing a gene therapy called SRP-6004 for people with limb girdle muscular dystrophy type 2B/R2, a rare muscle-weakening disease. The goal was to see if a single IV infusion of the therapy is safe and can help the body produce a missing prot…
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:20 UTC
-
Experimental gene therapy tested for rare muscular dystrophy
Disease control Stopped earlyThis early-stage trial tested a gene therapy called SRP-9004 in just 4 people with limb girdle muscular dystrophy type 2D/R3, a rare muscle-weakening disease. The main goal was to check safety, not effectiveness. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:47 UTC
-
Experimental gene therapy targets Tay-Sachs and sandhoff in kids
Disease control Stopped earlyThis early-stage trial tested a gene therapy called AXO-AAV-GM2 in children with Tay-Sachs or Sandhoff disease, rare and fatal genetic brain disorders. The therapy delivers healthy genes directly into the brain and spinal fluid to try to restore a missing enzyme. The study was te…
Phase 1 • Sponsor: Terence Flotte • Aim: Disease control
Last updated Jun 26, 2026 13:03 UTC
-
New PET tracer aims to spot Parkinson's protein in living brains
Diagnosis Stopped earlyThis early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with P…
Early phase 1 • Sponsor: Invicro • Aim: Diagnosis
Last updated Jul 29, 2026 00:00 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis Stopped earlyThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis Stopped earlyThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Corn could be key to saving your eyesight
Prevention Stopped earlyThis study looked at whether eating corn rich in zeaxanthin (a natural pigment) could increase the density of the macular pigment in the eye, which may help prevent age-related macular degeneration (AMD), a leading cause of blindness. Nine healthy volunteers aged 20-35 ate a dail…
Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Can a breathing gadget calm anxious teens?
Symptom relief Stopped earlyThis study tests whether a biofeedback breathing system called Freespira can reduce anxiety and panic symptoms in young people aged 9 to 17. Over 8 weeks, one group uses the device while a control group waits. The goal is to see if the device helps lower anxiety scores on a stand…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief Stopped earlyThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a synthetic cannabinoid calm agitation in frontotemporal dementia?
Symptom relief Stopped earlyThis phase 2 trial tests whether nabilone, a synthetic cannabinoid, can reduce agitation in people with frontotemporal dementia (FTD). Participants receive both nabilone and a placebo in random order to compare effects. The study includes adults with behavioral variant FTD or pri…
Phase 2 • Sponsor: Simon Ducharme, MD • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Tiny incision, big relief? ultrasound procedure challenges carpal tunnel surgery
Symptom relief Stopped earlyThis study compared a new, minimally invasive ultrasound-guided procedure to standard surgery for carpal tunnel syndrome. The goal was to see if the new technique could provide similar relief with a smaller incision and faster recovery. Only 7 people were enrolled before the stud…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief Stopped earlyThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Nerve block or antidepressant? study tests two migraine treatments Head-to-Head
Symptom relief Stopped earlyThis study compares two treatments for transformed migraine (chronic daily headache): a sphenopalatine ganglion nerve block using lidocaine gel applied inside the nose, versus daily oral amitriptyline (Elavil), an antidepressant often used for migraine prevention. Ten adults aged…
Phase 4 • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a nerve pain drug and exercise ease long COVID fatigue?
Symptom relief Stopped earlyThis study tests whether the drug pregabalin, alone or with a rehabilitation program, can reduce chronic fatigue in people with post-COVID syndrome. Participants are adults aged 18 to 65 who had COVID-19 at least six months ago and still feel very tired. The trial compares four g…
Phase 2 • Sponsor: National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Parkinson's drug side effect targeted by antioxidant NAC – but trial stalls
Symptom relief Stopped earlyThis study tested whether N-acetylcysteine (NAC), an antioxidant, could help reduce impulse control disorders caused by Parkinson's medications. Only 14 people with mild-to-moderate symptoms were enrolled before the trial was stopped early. The goal was to see if 10 weeks of NAC …
Phase 3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
Lavender scent tested to ease Women's pain and anxiety during procedure
Symptom relief Stopped earlyThis study tested whether smelling lavender essential oil before and during an office hysteroscopy (a procedure to look inside the uterus) could lower women's anxiety and pain. Twenty-two women were randomly assigned to inhale either lavender oil or distilled water (placebo). The…
Phase 2 • Sponsor: University of Florida • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New radiation technique aims to calm tremors without surgery
Symptom relief Stopped earlyThis study tested a new way to treat hand tremors caused by essential tremor or Parkinson's disease using a linear accelerator, a common radiation machine. Instead of one large dose, the radiation was given in three smaller sessions to protect healthy brain tissue. The goal was t…
Phase 2 • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jun 27, 2026 12:37 UTC
-
New therapy targets memory doubts to curb OCD checking
Symptom relief Stopped earlyThis study tested a new, short therapy module for people with obsessive-compulsive disorder (OCD) who struggle with compulsive checking. The therapy focuses on fixing unhelpful beliefs about memory that drive the urge to check. Researchers aimed to see if this approach reduces ch…
Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Mindfulness app for anxiety in underserved groups fizzles out early
Symptom relief Stopped earlyThis study tested a smartphone app that teaches mindfulness meditation to help Black and Latino adults with anxiety during the COVID-19 pandemic. About 400 participants were assigned to one of two mindfulness programs or a waitlist. The trial was terminated early, so we don't hav…
Sponsor: University of North Carolina, Chapel Hill • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief Stopped earlyThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Personalized exercise trial for chronic fatigue ends early
Symptom relief Stopped earlyThis study tested whether a personalized exercise program could reduce fatigue in people with chronic fatigue syndrome. About 101 participants were planned, but the trial was terminated early. The approach involved tailoring aerobic and resistance exercises based on weekly fatigu…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain zaps for pain and fatigue: a quick fix?
Symptom relief Stopped earlyThis study looked at whether a brief, noninvasive brain stimulation technique called tDCS could immediately reduce pain and improve function in people with fibromyalgia or chronic fatigue syndrome. About 20 participants received one session, and researchers measured changes in pa…
Sponsor: Hospital Donostia • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief Stopped earlyThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase 2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Robot trainer aims to help Parkinson's patients walk better
Symptom relief Stopped earlyThis study tested a robotic device called the G-EO Gait Trainer to help people with Parkinson's disease improve their walking. The device supports the body and guides leg movements to make walking practice safer and more effective. The trial was terminated early, so only limited …
Sponsor: Indiana University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can a blood injection boost carpal tunnel surgery results?
Symptom relief Stopped earlyThis study looked at whether adding platelet-rich plasma (PRP) to standard carpal tunnel release surgery helps people with severe carpal tunnel syndrome. The trial planned to enroll 15 adults with severe nerve damage. It compared surgery with PRP to surgery alone. The study was t…
Sponsor: Michael Fredericson, MD • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
HIV-Positive Men's mental health study shuts down after just one participant
Symptom relief Stopped earlyThis study aimed to see if acceptance and commitment therapy (ACT), a type of talk therapy, could help HIV-positive men with mental health issues like stress and anxiety. Only one person enrolled before the study was stopped early. Because of this, no meaningful results were obta…
Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 12:09 UTC
-
Mindfulness may ease anxiety for heart device patients
Symptom relief Stopped earlyThis study tested whether a mindfulness program (including meditation, body scans, and gentle yoga) could help people with implanted heart devices like ICDs or pacemakers feel less anxious, stressed, and depressed. The study planned to enroll 34 adults who had recently received s…
Sponsor: Chien Chih-Yin • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Walking poles tested for Parkinson's: a simple step forward?
Symptom relief Stopped earlyThis study looked at whether using walking poles during an 8-week independent walking program could improve walking and activity levels in people with Parkinson's disease. Eleven participants were assigned to walk with or without poles at least three times a week. The trial was t…
Sponsor: Pacific Northwest University of Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief Stopped earlyThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Parkinson's sleep study halted early – what we know
Symptom relief Stopped earlyThis study looked at whether the drug safinamide (Xadago) could improve sleep quality in people with Parkinson's disease. Eleven participants took safinamide for 12 weeks while their sleep was measured. The trial was terminated early, so the results are not conclusive.
Phase 4 • Sponsor: Alain Kaelin • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief Stopped earlyThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Parkinson's apathy drug trial stalls after just 8 patients
Symptom relief Stopped earlyThis study tested whether istradefylline, a drug already approved for motor symptoms in Parkinson's, could also improve apathy and motivation. Only 8 people enrolled before the trial was terminated early. The results are too limited to draw any conclusions.
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Brain pacemaker tested for uncontrollable tics
Symptom relief Stopped earlyThis study tested whether deep brain stimulation (DBS) could help people with severe Tourette syndrome whose symptoms don't improve with medication. Researchers placed tiny electrodes in a part of the brain called the thalamus to try to calm abnormal signals that cause tics. Only…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Online therapy steps up against OCD in new study
Symptom relief Stopped earlyThis study tested whether a stepped-care approach using internet-based cognitive behavioral therapy (ICBT) works as well as group therapy or standard medical care for adults with obsessive-compulsive disorder (OCD). 46 adults in China received one of the three treatments for 6 we…
Sponsor: Shanghai Mental Health Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Can zapping two brain areas at once stop Parkinson's freezing?
Symptom relief Stopped earlyThis study tested whether a high-dose magnetic stimulation (TMS) targeting both motor and cognitive brain areas could better reduce freezing of gait in people with Parkinson's disease compared to standard low-dose stimulation of just the motor area. The trial planned to enroll 64…
Sponsor: Anhui Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 07:58 UTC
-
Calm app tested on stressed doctors – but study cut short
Symptom relief Stopped earlyThis study looked at whether using the Calm meditation app could help medical residents and fellows at Banner University Medical Center Phoenix feel less stressed, anxious, or burned out during the COVID-19 pandemic. Only 7 people signed up, and the study was stopped early, so we…
Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
CBD study for baby seizures halted early
Symptom relief Stopped earlyThis study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was termina…
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Parkinson's inhaler trial halted after just 8 patients
Symptom relief Stopped earlyThis study tested an inhaled form of apomorphine (AZ-009) to quickly treat 'OFF' episodes in people with Parkinson's disease—times when symptoms like stiffness or trouble moving return between regular medication doses. The trial was planned for more participants but was terminate…
Phase 2 • Sponsor: Alexza Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
Can personalized recall timing boost word learning in kids with DLD?
Knowledge-focused Stopped earlyThis study explores whether tailoring when children with developmental language disorder (DLD) practice recalling new words can improve their learning. Researchers compare a standard fixed schedule to an adaptive one that adjusts to each child's progress. Four- and five-year-olds…
Sponsor: Purdue University • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Can genetics predict the worsening of geographic atrophy?
Knowledge-focused Stopped earlyThis study follows people with geographic atrophy, a severe form of age-related macular degeneration that causes blind spots, to see how their vision changes over time. Researchers will measure visual function, such as reading speed and sensitivity to light, and track the growth …
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Can a coordinated care team ease the aftermath of intensive care?
Knowledge-focused Stopped earlyThis pilot study tests a new approach to supporting people after a stay in the intensive care unit (ICU). Many ICU survivors face ongoing psychological and physical challenges, such as depression, anxiety, and disability. The intervention involves a case manager who coordinates a…
Sponsor: Region Stockholm • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
Knowledge-focused Stopped earlyThis study measures levels of a protein called NT-3 in the blood of people with peripheral neuropathy or Charcot-Marie-Tooth disease. Researchers will compare these levels with measures of muscle strength, mobility, and daily function. The goal is to see whether NT-3 levels corre…
Sponsor: Zarife Sahenk • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Brain scans reveal why dementia changes personality
Knowledge-focused Stopped earlyThis study investigates how Alzheimer's disease and frontotemporal dementia alter a person's sense of self and ability to understand others. Researchers will compare patients with healthy older adults using questionnaires and brain imaging. The goal is to link changes in self-awa…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Zapping the brain to unravel OCD in kids
Knowledge-focused Stopped earlyThis study looked at how a gentle brain stimulation technique called tDCS affects thinking and behavior in children aged 10-17 with obsessive-compulsive disorder (OCD). The goal was to understand brain processes linked to OCD, not to treat the condition. Only 6 participants were …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Psychedelics rewire Brain's learning? yale study investigates
Knowledge-focused Stopped earlyThis observational study at Yale University is recruiting 200 people who are already taking part in another trial where they may receive a serotonergic psychedelic (like psilocybin or LSD) or a placebo. Researchers want to understand how these substances change the brain's inform…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Tafamidis tablet vs capsule: which works better?
Knowledge-focused Stopped earlyThis early-stage study aimed to compare how a tablet form of tafamidis is absorbed in the body compared to the existing capsule form. It involved 24 healthy adults who took a single dose of each form under fed conditions. The study was terminated early, so results may be limited.
Phase 1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused Stopped earlyThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Scientists probe Brain's consciousness switch during anesthesia
Knowledge-focused Stopped earlyThis study looked at how anesthesia changes brain activity in people with Parkinson's disease or essential tremor who were already scheduled for deep brain stimulation (DBS) surgery. Researchers recorded brain signals during a short period of anesthesia to understand which circui…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Tiny genetic clues may unlock eye disease mysteries
Knowledge-focused Stopped earlyThis study looked at people with cone disorders, a type of inherited eye disease that affects color vision and sharp sight. Researchers analyzed genetic changes of unknown significance to see if they cause disease. The goal was to improve genetic diagnosis, not to test a treatmen…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Peeling eye membrane during retinal surgery: help or hype?
Knowledge-focused Stopped earlyThis study looked at whether peeling a thin membrane inside the eye (the internal limiting membrane) during surgery for a detached retina helps patients see better and prevents scar tissue. The trial was stopped early after enrolling only 21 people, so the results are not strong …
Sponsor: Vienna Institute for Research in Ocular Surgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Gut hormone shot aims to strengthen fragile bones in kids with muscle diseases
Knowledge-focused Stopped earlyThis study tested whether two gut hormones, GIP and GLP-2, could reduce bone breakdown in children with spinal muscular atrophy, cerebral palsy, or Duchenne muscular dystrophy who use wheelchairs. Participants received a liquid meal and then either a hormone injection or a placeb…
Sponsor: University of Copenhagen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New eye camera could spot hidden signs of blindness
Knowledge-focused Stopped earlyThis study tested a new, non-invasive eye imaging method called hyperspectral imaging. It takes pictures of the back of the eye using many different colors of light to find details not visible with standard cameras. About 679 adults with healthy eyes or eye diseases like diabetic…
Sponsor: Center for Eye Research Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists hunt for clues in rare genetic brain disorder
Knowledge-focused Stopped earlyThis study aimed to observe how MECP2 duplication syndrome progresses over time by measuring biological markers in spinal fluid and blood, and by tracking changes in development, behavior, and seizures. It enrolled 29 males aged 1 month to 65 years with a confirmed genetic diagno…
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Brain wave test could spot stubborn depression
Knowledge-focused Stopped earlyThis study aimed to find brain and movement markers in people with a type of depression that doesn't respond to standard antidepressants, called anhedonic depression. Researchers measured brain waves (P300), walking speed, and hand movements in 36 participants. The goal was to id…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Rare disease study aims to map MLIV's natural course
Knowledge-focused Stopped earlyThis study followed 7 people with Mucolipidosis Type IV (MLIV) to learn how the disease naturally progresses. Researchers used tests like neuropsychological exams, blood and urine tests, and brain MRIs to find better ways to measure the disease. The goal was to improve future cli…
Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
Scientists dig into DNA to unravel rare eye disorders
Knowledge-focused Stopped earlyThis study looked at over 100 people with inherited retinal dystrophies, a group of rare eye diseases that can cause vision loss. Researchers collected genetic and eye exam data to find links between specific gene mutations and symptoms. The goal was to better understand these di…
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New survey aims to better measure life quality in pituitary tumor patients
Knowledge-focused Stopped earlyThis study tested a new questionnaire called Prolac-10 to see if it can accurately measure quality of life in people with prolactinoma (a type of pituitary tumor) who are starting medical treatment. Only 8 people took part before the study was stopped early. The goal was to check…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Drug interaction study for radiprodil halted early
Knowledge-focused Stopped earlyThis early-stage study looked at how two common drugs (carbamazepine and itraconazole) change the levels of radiprodil in the blood of 30 healthy adults. The goal was to understand safety and dosing for future use in neurological conditions like tuberous sclerosis. However, the s…
Phase 1 • Sponsor: GRIN Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Rare disease mystery: scientists watch AMN progress in hopes of finding a cure
Knowledge-focused Stopped earlyThis study followed 65 adult men with a rare inherited nerve disease called AMN (a form of spastic paraplegia) to understand how their symptoms change over time. Researchers collected data on walking ability and quality of life. The goal was to fill gaps in knowledge about the di…
Sponsor: SwanBio Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Hidden heart condition: study seeks to uncover missed diagnosis in heart failure patients
Knowledge-focused Stopped earlyThis study aims to find out how common transthyretin amyloidosis cardiomyopathy (ATTR-CM) is in Russian patients with a certain type of heart failure. Researchers will review medical records and then invite some patients for extra heart tests to confirm or rule out ATTR-CM. The g…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:47 UTC
-
One-Person study aims to unlock FSHD mysteries
Knowledge-focused Stopped earlyThis study looked at one person with facioscapulohumeral muscular dystrophy (FSHD) to better understand the disease. Researchers examined muscle tissue and checked for specific biomarkers. The goal was to learn more about how FSHD affects the body, not to test a treatment.
Sponsor: Nationwide Children's Hospital • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:43 UTC
-
Gene therapy for krabbe disease: did it last?
Knowledge-focused Stopped earlyThis study follows up on children with Krabbe disease who received a one-time gene therapy infusion (FBX-101) in earlier trials. Researchers will monitor safety and measure motor skills over time. Only 2 participants are enrolled, so results are very limited.
Sponsor: Forge Biologics, Inc • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:47 UTC
-
New implant could track seizures for months
Knowledge-focused Stopped earlyThis study tested a small device implanted under the scalp to record brain waves (EEG) continuously for up to 12 weeks in people with epilepsy. The goal was to see if it could detect seizures better than standard short-term hospital monitoring and patient diaries. The trial invol…
Sponsor: UNEEG Medical A/S • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:35 UTC
-
Treadmill training may slow Parkinson's by fighting inflammation
Knowledge-focused Stopped earlyThis study looked at whether intensive treadmill exercise can improve motor symptoms and reduce inflammation in people with early-stage Parkinson's disease. Researchers measured changes in movement scores and blood markers of nerve damage and inflammation in 30 patients who eithe…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:10 UTC
-
A multicenter, open-label extension (OLE) study to evaluate the safety, pharmacodynamics, and clinical effects of WVE-004 in patients with C9orf72-associated amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD)
Stopped earlyThis is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented mutation in the C9orf72 gene. To participate in the…
Phase 1/2 • Sponsor: Wave Life Sciences USA, Inc.
Last updated Sep 09, 2026 15:00 UTC
-
Project QUIT+: adapting and testing a smoking cessation intervention for transgender and gender expansive individuals
Stopped earlySmoking remains the leading preventable cause of death in the United States, and there are persistent and significant disparities in tobacco use among transgender and gender diverse (TGD) individuals. Stigma, discrimination, gender dysphoria, and other gender minority stressors l…
Sponsor: Massachusetts General Hospital
Last updated Sep 09, 2026 15:00 UTC